R&D Trends

Collaborative Cancer Cloud expands to drive medicines to patients faster

Monday, April 11, 2016

The Dana-Farber Cancer Institute (DFCI) of Boston and the Ontario Institute for Cancer Research (OICR) in Toronto have joined the Collaborative Cancer Cloud, a partnership formed in August 2015 by the Knight Cancer Institute at Oregon Health and Science University (OHSU) of Portland, Oregon, and Intel. By allowing research institutions to securely share genomic, imaging and clinical data on a precision medical analytics platform, the Collaborative Cancer Cloud is positioning itself to make rapid strides in cancer research and lifesaving therapies.

[Read More]

Sosei subsidiary Heptares and Allergan partner

Thursday, April 7, 2016

Sosei Group‘s wholly-owned subsidiary Heptares Therapeutics has entered into a definitive agreement with Allergan Pharmaceuticals International, a wholly owned subsidiary of Allergan, a global pharmaceutical company, under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.

[Read More]

FEI partners to form Cryo-EM research consortium

Tuesday, April 5, 2016

FEI has partnered to form the “Cambridge Pharmaceutical Cryo-EM Consortium.” Partners include five pharmaceutical companies—Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Center. As part of the three-year agreement, FEI will provide sample preparation and data collection services on a Titan Krios cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.

[Read More]

Report: Slowest quarter for venture-backed IPOs since 2011

Tuesday, April 5, 2016

Six venture-backed initial public offerings (IPOs) raised $574.5 million in the first quarter of 2016, according to the Exit Poll Report by Thomson Reuters and the National Venture Capital Association (NVCA). This marks the slowest quarter for venture-backed IPOs since the third quarter of 2011. By merger and acquisition (M&A), 79 venture-backed M&A deals were reported in the first quarter, 20 of which reported an aggregate deal value of $4.8 billion.   

[Read More]

Dotmatics, BioByte partner to speed drug candidate selection

Tuesday, April 5, 2016

Dotmatics, a provider of scientific informatics solutions and services to the life sciences industry, announced a partnership with BioByte, producer of the industry gold standard partition coefficient calculator (ClogP). This deal will enable users of the Dotmatics Platform including Vortex and Browser to calculate ClogP seamlessly within the applications. This will streamline the research process and speed up the selection of potential drug candidates.  

[Read More]

Revisiting industry partnerships with the Department of Veterans Affairs

Monday, April 4, 2016

Contract research organizations (CROs) should consider partnering with the Department of Veterans Affairs (VA) when conducting clinical trials, according to an attendee at the recent Clinical Trial Collaborations conference in Boston, Massachusetts. “The atmosphere is right for increasing the number of industry-VA collaborations,” said Dawn McKenna, executive director of the Bedford VA Research Corporation in Bedford, Massachusetts. McKenna spent years working in the pharmaceutical research and development industry as well as government and nonprofit areas before taking the helm in Bedford last year.   

[Read More]

Megafunds as an avenue to boost drug development

Monday, April 4, 2016

With skyrocketing drug development costs and increasing pressure on traditional resources, creation of private megafunds to boost drug research seems to be gaining more traction.
A recent initiative is an $866 million development fund established by Mitsui & Co., contract researcher Quintiles and other investors. The new private equity fund will invest mainly in drugs from major U.S. and European companies that are in phase III clinical trials, particularly cancer therapies and treatments for central nervous system disorders.

[Read More]

Dana-Farber, Ontario Institute join collaborative cancer cloud

Friday, April 1, 2016

The Knight Cancer Institute at Oregon Health & Science University and Intel are expanding participation in the Collaborative Cancer Cloud, a distributed precision medicine analytics platform, to include Dana-Farber Cancer Institute and Ontario Institute for Cancer Research. The institutions will join the OHSU Knight Cancer Institute in leveraging Intel’s technology to securely share and analyze their collectively large amounts of data, while preserving the privacy and security of patient data at each site.

[Read More]

Orig3n, Sharp Edge Labs ink drug discovery alliance

Monday, March 28, 2016

ORIG3N, a regenerative medicine provider, and Sharp Edge Labs, a drug discovery and development company focused on genetic disorders, have entered into a drug discovery alliance. As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders.

[Read More]